AQXP vs. AUPH, LBPH, OCUL, ARCT, PLRX, PRTC, NRIX, ALXO, SAGE, and DNTH
Should you be buying Aquinox Pharmaceuticals stock or one of its competitors? The main competitors of Aquinox Pharmaceuticals include Aurinia Pharmaceuticals (AUPH), Longboard Pharmaceuticals (LBPH), Ocular Therapeutix (OCUL), Arcturus Therapeutics (ARCT), Pliant Therapeutics (PLRX), PureTech Health (PRTC), Nurix Therapeutics (NRIX), ALX Oncology (ALXO), Sage Therapeutics (SAGE), and Dianthus Therapeutics (DNTH). These companies are all part of the "medical" sector.
Aurinia Pharmaceuticals (NASDAQ:AUPH) and Aquinox Pharmaceuticals (NASDAQ:AQXP) are both small-cap medical companies, but which is the better investment? We will contrast the two businesses based on the strength of their profitability, earnings, valuation, risk, institutional ownership, dividends, analyst recommendations, community ranking and media sentiment.
Aurinia Pharmaceuticals received 267 more outperform votes than Aquinox Pharmaceuticals when rated by MarketBeat users. Likewise, 73.03% of users gave Aurinia Pharmaceuticals an outperform vote while only 71.88% of users gave Aquinox Pharmaceuticals an outperform vote.
36.8% of Aurinia Pharmaceuticals shares are owned by institutional investors. Comparatively, 71.7% of Aquinox Pharmaceuticals shares are owned by institutional investors. 4.3% of Aurinia Pharmaceuticals shares are owned by company insiders. Comparatively, 4.0% of Aquinox Pharmaceuticals shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock is poised for long-term growth.
Aurinia Pharmaceuticals presently has a consensus target price of $10.00, indicating a potential upside of 105.34%. Given Aquinox Pharmaceuticals' higher possible upside, equities analysts clearly believe Aurinia Pharmaceuticals is more favorable than Aquinox Pharmaceuticals.
Aquinox Pharmaceuticals has lower revenue, but higher earnings than Aurinia Pharmaceuticals.
Aurinia Pharmaceuticals has a beta of 1.36, meaning that its stock price is 36% more volatile than the S&P 500. Comparatively, Aquinox Pharmaceuticals has a beta of -7.37, meaning that its stock price is 837% less volatile than the S&P 500.
Aquinox Pharmaceuticals has a net margin of 0.00% compared to Aquinox Pharmaceuticals' net margin of -44.45%. Aquinox Pharmaceuticals' return on equity of -20.10% beat Aurinia Pharmaceuticals' return on equity.
In the previous week, Aurinia Pharmaceuticals had 3 more articles in the media than Aquinox Pharmaceuticals. MarketBeat recorded 3 mentions for Aurinia Pharmaceuticals and 0 mentions for Aquinox Pharmaceuticals. Aurinia Pharmaceuticals' average media sentiment score of 0.00 beat Aquinox Pharmaceuticals' score of -0.02 indicating that Aquinox Pharmaceuticals is being referred to more favorably in the news media.
Summary
Aurinia Pharmaceuticals beats Aquinox Pharmaceuticals on 10 of the 15 factors compared between the two stocks.
Get Aquinox Pharmaceuticals News Delivered to You Automatically
Sign up to receive the latest news and ratings for AQXP and its competitors with MarketBeat's FREE daily newsletter.
This chart shows the number of new MarketBeat users adding AQXP and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Aquinox Pharmaceuticals Competitors List
Related Companies and Tools
